Monday, 28 September 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Financial Results · Q4 FY26

OneSource Specialty Pharma Q4 FY26 Results: Net Profit ₹4.6 Cr, Down 95.3% YoY

OneSource Specialty Pharma Ltd reported revenue from operations of ₹428.2 Cr (+0.5% YoY) and net profit of ₹4.6 Cr (-95.3% YoY) for Q4 FY26.

Q4 FY26 at a glance · ₹ crore
MetricQ4 FY26Q3 FY26Q4 FY25
Revenue from operations428.2290.3426.0
Other income2.14.62.9
Total income430.3295.0428.8
Profit before exceptional items & tax-0.3-85.983.5
Exceptional items0.0-7.10.0
Profit before tax-0.3-93.083.5
Net profit4.6-88.798.5
Operating margin-0.1%-31.5%19.5%

A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.

Growth
Net profit, year on year-95.30%
Revenue, year on year+0.50%
Source

NSE results filing, NSE: ONESOURCE. Figures extracted from the filing.

Read the filing ↗

OneSource Specialty Pharma Ltd: key numbers

Share price
₹1,602.60
Market cap
₹18,377 Cr
Revenue (annual)
₹1,422 Cr
Net profit (annual)
₹-73.80 Cr
P/E (TTM)
-378.0×Sector 50.4×
Promoter holding
30.48%+0.00% QoQ
FII holding
19.19%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from OneSource Specialty Pharma Ltd

All →
19:39 IST BSE
Employee Stock Options

OneSource Specialty Pharma Employee Stock Options

Onesource Specialty Pharma Limited has allotted 900 equity shares under its Employee Stock Option Plan. This allotment updates the company's total paid-up share capital.

19:26 IST NSE
Employee Stock Options

OneSource Specialty Pharma Employee Stock Options

OneSource Specialty Pharma allotted 900 shares under its ESOP 2021 scheme at an exercise price of ₹278 per share, totaling ₹0.03 Crore.

Value
₹0.03 Cr
23:02 IST BSE
Management Change

OneSource Specialty Pharma Management Change

Onesource Specialty Pharma Limited appointed B S R & Co LLP as its Statutory Auditor for a 60-month term, effective September 23, 2026.

23:39 IST BSE
Other Announcement

OneSource Specialty Pharma Other Announcement

OneSource Specialty Pharma Ltd appointed M/s B S R & Co LLP as its Statutory Auditors for a five-year term ending at the 24th AGM.

23:34 IST BSE
Annual General Meeting

OneSource Specialty Pharma Annual General Meeting

OneSource Specialty Pharma held its 19th Annual General Meeting on September 23, 2026. Shareholders transacted ordinary and special business items, including re-appointments and related party approvals.

17:02 IST BSE
Annual General Meeting

OneSource Specialty Pharma Annual General Meeting

OneSource Specialty Pharma issued an addendum to its 19th AGM notice regarding additional disclosures for agenda items about material related party transactions.